RxDoctor Payments Data

Trevor Wilde, DO

Family Medicine · Saint Anthony, IDNPI 1538422019

Payments from drug & device makers

$482in general payments, 2019–2025

Across 21 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$228
  • Dornier Medtech America, Inc$119
  • Amgen$29
  • Organon$19
  • Johnson & Johnson$19
  • GSK$14
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$46897%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)11$228
Dornier Medtech America, Inc1$119
Amgen2$29
Organon1$19
Johnson & Johnson1$19
GSK1$14
Boston Scientific1$14
Novo Nordisk1$14
Pfizer1$14
Biohaven Pharmaceutical Holding Company Ltd.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$482 in reported general payments places this provider in the 60th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$4,032
Medicare patients
92
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase13$66,362
OzempicSemaglutide44$60,360
FarxigaDapagliflozin Propanediol28$38,549
TradjentaLinagliptin22$26,702
XareltoRivaroxaban19$21,171
NeuproRotigotine17$19,319
JardianceEmpagliflozin17$16,574
EliquisApixaban19$15,876
LinzessLinaclotide21$12,691
Ondansetron Hcl18$12,570
Spiriva HandihalerTiotropium Bromide12$9,742
MyrbetriqMirabegron18$8,755
Ajovy SyringeFremanezumab-Vfrm11$7,725
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$5,079
Celecoxib27$2,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$60,36044 claims
Johnson & JohnsonXarelto$19$21,17119 claims
PfizerEliquis$14$15,87619 claims
AbbVieLinzess$228$12,69121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 803 family medicine providers in Idaho.

Other family medicine in Saint Anthony

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →